- United States
- /
- Biotech
- /
- NasdaqGS:ARQT
Exploring 3 High Growth Tech Stocks in the US Market
Reviewed by Simply Wall St
The United States market has experienced a 2.9% increase in the last week and is up 11% over the past year, with earnings projected to grow by 14% annually in the coming years. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation, robust revenue growth, and adaptability to evolving technological trends.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 20.44% | 29.79% | ★★★★★★ |
TG Therapeutics | 26.18% | 37.61% | ★★★★★★ |
Travere Therapeutics | 28.43% | 65.01% | ★★★★★★ |
AVITA Medical | 27.74% | 55.36% | ★★★★★★ |
TKO Group Holdings | 22.48% | 25.17% | ★★★★★★ |
Alvotech | 31.17% | 100.18% | ★★★★★★ |
Clene | 60.86% | 63.07% | ★★★★★★ |
Alnylam Pharmaceuticals | 22.76% | 58.40% | ★★★★★★ |
Lumentum Holdings | 21.55% | 119.67% | ★★★★★★ |
Ascendis Pharma | 32.36% | 59.79% | ★★★★★★ |
Click here to see the full list of 237 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Arcutis Biotherapeutics (NasdaqGS:ARQT)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Arcutis Biotherapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for dermatological diseases, with a market cap of $2.05 billion.
Operations: Arcutis Biotherapeutics focuses on the development and commercialization of dermatological treatments, generating $196.54 million in revenue from its pharmaceuticals segment.
Arcutis Biotherapeutics has demonstrated a robust trajectory in addressing atopic dermatitis with its recent Health Canada approval for ZORYVE® cream, marking a significant advancement in steroid-free treatments. The company's strategic focus on dermatological conditions is underscored by a 230% increase in annual revenue to $196.54 million and a reduced net loss from $262.14 million to $140.04 million year-over-year, reflecting effective management and promising market acceptance. With R&D expenses aligning closely with these innovative pursuits, Arcutis is positioning itself as a key player in specialized healthcare solutions, leveraging clinical successes to potentially secure long-term growth and profitability within this niche market.
IREN (NasdaqGS:IREN)
Simply Wall St Growth Rating: ★★★★★☆
Overview: IREN Limited owns and operates bitcoin mining data centers, with a market capitalization of approximately $1.68 billion.
Operations: The company's primary revenue stream is derived from building and operating data center sites dedicated to bitcoin mining, generating approximately $285.77 million.
Amidst a volatile market, IREN stands out with its aggressive expansion and innovative approach in the tech sector. Recently, the company announced a significant 600MW grid connection for its Sweetwater 2 project, underscoring its commitment to enhancing data center capabilities. This move aligns with an impressive forecasted annual revenue growth of 49.6% and earnings growth of 96.26%, positioning IREN well above industry averages. Moreover, despite substantial shareholder dilution over the past year, IREN's focus on high-value technology investments is evident in its R&D spending trends which are crucial for sustaining long-term competitiveness in the rapidly evolving tech landscape.
- Navigate through the intricacies of IREN with our comprehensive health report here.
Assess IREN's past performance with our detailed historical performance reports.
DigitalOcean Holdings (NYSE:DOCN)
Simply Wall St Growth Rating: ★★★★★☆
Overview: DigitalOcean Holdings, Inc. operates a global cloud computing platform through its subsidiaries, with a market capitalization of approximately $3.49 billion.
Operations: DigitalOcean Holdings generates revenue primarily from its Internet Software & Services segment, amounting to $780.62 million. The company provides cloud computing services across various regions, including North America, Europe, and Asia.
DigitalOcean Holdings, Inc. has demonstrated a robust financial performance with a 335.3% increase in annual net income, significantly outpacing the IT industry's average decline of 7.8%. This growth is underpinned by strategic investments in R&D and recent innovations like the GenAI Platform, which simplifies AI deployment for various business applications, enhancing its competitive edge in tech solutions. The company also forecasts an earnings growth of 20.5% annually, surpassing broader market expectations of 13.9%, indicating strong future prospects despite slower revenue growth projections at 12.2% annually compared to the market's average of 8.4%.
- Unlock comprehensive insights into our analysis of DigitalOcean Holdings stock in this health report.
Understand DigitalOcean Holdings' track record by examining our Past report.
Seize The Opportunity
- Unlock more gems! Our US High Growth Tech and AI Stocks screener has unearthed 234 more companies for you to explore.Click here to unveil our expertly curated list of 237 US High Growth Tech and AI Stocks.
- Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:ARQT
Arcutis Biotherapeutics
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
High growth potential with adequate balance sheet.
Similar Companies
Market Insights
Community Narratives
